Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2005-12-20
2005-12-20
Kross, Frederick (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S170000, C514S177000, C514S179000, C514S841000, C514S843000, C514S874000
Reexamination Certificate
active
06977250
ABSTRACT:
The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering progestin products, either alone or in combination with other agents such as estrogen products.
REFERENCES:
patent: 3608075 (1971-09-01), Glen et al.
patent: 3957982 (1976-05-01), Lachnit-Fixson et al.
patent: 3969502 (1976-07-01), Lachnit-Fixson
patent: 4390531 (1983-06-01), Edgren
patent: 4530839 (1985-07-01), Pasquale
patent: 4544554 (1985-10-01), Pasquale
patent: 4594340 (1986-06-01), Partridge et al.
patent: 4616006 (1986-10-01), Pasquale
patent: 4621079 (1986-11-01), Lachnit-Fixson et al.
patent: 4628051 (1986-12-01), Pasquale
patent: 4757061 (1988-07-01), Faustini et al.
patent: 4760053 (1988-07-01), Labrie
patent: 4800198 (1989-01-01), DuLuca et al.
patent: 4808578 (1989-02-01), Faustini et al.
patent: 4808616 (1989-02-01), Buzzetti et al.
patent: 4814327 (1989-03-01), Ottow et al.
patent: 4817819 (1989-04-01), Kelly
patent: 4840943 (1989-06-01), Buzzetti et al.
patent: 4870069 (1989-09-01), Ottow et al.
patent: 4904650 (1990-02-01), Buzzetti et al.
patent: 4921843 (1990-05-01), Pasquale
patent: 4931283 (1990-06-01), Tsuk
patent: 4933184 (1990-06-01), Tsuk
patent: 4954790 (1990-09-01), Barber
patent: 4962098 (1990-10-01), Boissonneault
patent: 5006518 (1991-04-01), Moguilewsky
patent: 5081114 (1992-01-01), Gourvest et al.
patent: 5086047 (1992-02-01), Gourvest et al.
patent: 5089488 (1992-02-01), Ottow et al.
patent: 5108995 (1992-04-01), Casper
patent: 5190935 (1993-03-01), Binderup et al.
patent: 5206229 (1993-04-01), Calverly et al.
patent: 5210081 (1993-05-01), Raveendranath et al.
patent: 5227375 (1993-07-01), Labrie et al.
patent: 5246925 (1993-09-01), DeLuca et al.
patent: 5256421 (1993-10-01), Casper
patent: 5262408 (1993-11-01), Bergink
patent: 5278155 (1994-01-01), Ikekawa et al.
patent: 5280023 (1994-01-01), Ehrlich et al.
patent: 5288717 (1994-02-01), Raveendranath et al.
patent: 5314694 (1994-05-01), Gale et al.
patent: 5362720 (1994-11-01), Labrie
patent: 5364847 (1994-11-01), Labrie et al.
patent: 5373004 (1994-12-01), DeLuca et al.
patent: 5374629 (1994-12-01), Calverley et al.
patent: 5380720 (1995-01-01), DeLuca et al.
patent: 5382573 (1995-01-01), Casper
patent: 5387582 (1995-02-01), Hansen
patent: 5389622 (1995-02-01), Posner et al.
patent: 5401731 (1995-03-01), Calverley et al.
patent: 5411949 (1995-05-01), Neef et al.
patent: 5416091 (1995-05-01), King
patent: 5418228 (1995-05-01), Bennick
patent: 5422119 (1995-06-01), Casper
patent: 5428029 (1995-06-01), Doran et al.
patent: 5434146 (1995-07-01), Labrie et al.
patent: 5446035 (1995-08-01), Neef et al.
patent: 5451574 (1995-09-01), Baggiolini et al.
patent: 5461041 (1995-10-01), Bergink et al.
patent: 5468736 (1995-11-01), Hodgen
patent: 5484782 (1996-01-01), DeLuca et al.
patent: 5486511 (1996-01-01), Weintraub et al.
patent: 5496813 (1996-03-01), Eugster et al.
patent: 5502044 (1996-03-01), Buzzetti et al.
patent: 5512554 (1996-04-01), Baggiolini et al.
patent: 5532228 (1996-07-01), Neef et al.
patent: 5536713 (1996-07-01), DuLuca et al.
patent: 5547947 (1996-08-01), Dore et al.
patent: 5552394 (1996-09-01), Hodgen
patent: 5554599 (1996-09-01), GrueSorenen et al.
patent: 5595970 (1997-01-01), Garfield et al.
patent: 5620705 (1997-04-01), Dong et al.
patent: 5633011 (1997-05-01), Dong et al.
patent: 5741786 (1998-04-01), Hamersma et al.
patent: 5747480 (1998-05-01), Gast
patent: 5770227 (1998-06-01), Dong et al.
patent: 5780497 (1998-07-01), Miller et al.
patent: 5783208 (1998-07-01), Yenkateshwaran et al.
patent: 5811416 (1998-09-01), Chwalisz et al.
patent: 5827876 (1998-10-01), Sabatucci
patent: 5855906 (1999-01-01), McClay
patent: 5858405 (1999-01-01), Gast
patent: 5876746 (1999-03-01), Jona et al.
patent: 5880137 (1999-03-01), Miller et al.
patent: 5888543 (1999-03-01), Gast
patent: 5891868 (1999-04-01), Cummings et al.
patent: 5898038 (1999-04-01), Yallampalli et al.
patent: 5922349 (1999-07-01), Elliesen et al.
patent: 5922542 (1999-07-01), Ralston et al.
patent: 5948775 (1999-09-01), Koko et al.
patent: 5962444 (1999-10-01), Cook et al.
patent: 5972377 (1999-10-01), Jona et al.
patent: 5985910 (1999-11-01), Miller et al.
patent: 5994337 (1999-11-01), Washburn et al.
patent: 5998137 (1999-12-01), Grainger et al.
patent: 6001846 (1999-12-01), Edwards et al.
patent: 6015805 (2000-01-01), Cook et al.
patent: 6020328 (2000-02-01), Cook et al.
patent: 6028064 (2000-02-01), Rodriguez
patent: 6034074 (2000-03-01), Rodriguez et al.
patent: 6310054 (2001-10-01), Rodriguez
patent: 6319911 (2001-11-01), Rodriguez
patent: 6444658 (2002-09-01), Rodriguez et al.
patent: 0 253 607 (1987-07-01), None
patent: 0 253 607 (1987-07-01), None
patent: 0 628 312 (1994-02-01), None
patent: WO 95/26730 (1995-10-01), None
patent: WO 98/10771 (1998-03-01), None
Allgood, V.E., et al., “Analysis Of Chicken Progesterone Receptor Function And Phosphorylation using An Adenovirus-Medicated Procedure For High-Efficiency DNA Transfer,”Biochemistry, 36(1):224-232 (1997).
Arends, M.J. et al., “Apoptosis: Mechanisms And Roles In Pathology,”Int. Rev. Exp. Pathol.,32:223-254 (1991).
Arrick, B.A., et al., “Differential Regulation Of Three Transforming Growth Factor b Species In Human Breast Cancer Cell Lines By Estradiol,”Cancer Res.,50:299-303 (1990).
Bai, W. et al., “Differential Phosphorylation Of Chicken Progesterone Receptor In Hormone-Dependent And Ligand-Independent Activation,” J. Biol. Chem., 272(16):10457-10463 (1997).
Bates, R.C. et al. “Involvement Of Integrins In Cell Survival,”Cancer Metastasis Rev, 14(3):191-203 (1995).
Berchuck, A. et al., “Regulation Of Growth Of Normal Ovarian Epithelial Cells And Ovarian Cancer Cell Lines By Transforming Growth, Factor-Beta,”Am. J. Obstet. Gynecol.,166:676-84 (1992).
Berchuck, A., et al., “The Role Of Peptide Growth Factors In Epithelial Ovarian Cancer,”Obstet. Gynecol, 75:255-62 (1990).
Brenner, R.M. et al., “Cyclic Changes In The Primate Oviduct And Endometrium. In:The Physiology Of Reproduction,”Knobil, E. et al., (eds), New York: Raven Press, pp. 541-569 (1994).
Bu, S.Z. et al., “Progesterone Induces Apoptosis And Up-Regulation of p53 Expression In Human Ovarian Carcinoma Cell Lines,”Cancer, 79:1944-1950 (1997).
Bundesverband der Pharmazeutishen Industrie, “Rote liste 1995,” Ecv. Edito Cantor,Aulendorf(DE), pp. 75023-75024 (1995).
Chan, L.N. et al., “N-(4-Hydroxyphenyl) Retinamide Prevents Development Of Tlymphomas In AKR/J Mice,”Anticancer Research, 17:499-503 (1997).
Cohen, J.J., “Apoptosis,”Immun. Today, 14:126-130 (1993).
Delia, D. et al., “N-(4-hydroxyphenyl) Retinamide Induces Apoptosis Of Malignant Hemopoietic Cell Lines Including Those Unresponsive To Retinoic Acid,”Cancer Res.,53(24):6036-41 (1993).
Eguchi, Y. et al., “Isolation And Characterization Of The Chicken bet-2 Gene: Expression In A Variety Of Tissues Including Lymphoid And Neuronal Organs In Adult And Embryo,”Nucleic Acids Research, 20(16):4187-4192 (1992).
el-Bayoumy, K. et al., “Chemo Prevention Of Cancer By Organoselenium Compounds,”J. Cell. Biochem, Suppl.,22:92-100 (1995).
Ellis, R. et al., “Mechanisms of Cell Death,”Ann. Rev. Cell. Bio.,17:663-698 (1991).
Evans, D.L. et al., “Molecular Evolution And Secondary Structural Conservation In The B-Cell Lymphoma Leukemia 2 (bcl-2) family Of Proto-Oncogene Products,”J. Mol. Evol.,41(6):775-83 (1995).
Fredrickson, T.N. et al., “Ovarian Tumors Of The Hen,”Environ Health Perspect, 73:35-44 (1987).
Gentry, L.E. et al., “Type I Transforming Growth Factor-Beta: Amplified Expression And Secretion Of Mature And Precursor Polypeptides In Chinese Hamster Ovary Cells,”Mol. Cell. Biol.,7:3418-27 (1987).
Grimes et al., “Primary Prevention Of Gynecologic Cancers,”Am. J. Obstetrics And Gynecology, 172(1):227-235 (1995).
Havrilesky, L.J., et al., “Regulation Of Apoptosis In N
Kross Frederick
Lewis Amy
New Life Pharmaceuticals Inc.
Nimrod Raymond N.
LandOfFree
Prevention of ovarian cancer by administration of progestin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention of ovarian cancer by administration of progestin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention of ovarian cancer by administration of progestin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3473338